Clinuvel set to accelerate phase III study of Scenesse
05 April, 2012 by Dylan Bushell-EmblingClunivel has reached an in-principle agreement with the US Food and Drug Administration to accelerate the phase III trials of Scenesse for the treatment of erythropoietic protoporphyria (EPP).
PolyNovo commences wound treatment trial
05 April, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) unit PolyNovo will soon trial its BTM technology as an implant to treat major burns and other full thickness wounds requiring a skin graft.
Changes to IP laws explained
02 April, 2012 by AusBiotechHow the changes in the 'Raising the Bar' Bill to intellectual property legislation will affect life science companies.
Early data show Bionomics' BNC105 effective against tumours
02 April, 2012 by Dylan Bushell-EmblingPreclinical data shows Bionomics' (ASX:BNO) BNC105 compound can be effective in treating platinum-resistant ovarian cancer tumours.
IQnovate to move to ASX
02 April, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX.
Merged drug developer nears ASX listing
02 April, 2012 by Dylan Bushell-EmblingBioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April.
Pharmaxis signs EU distribution deal for Bronchitol
30 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe.
Agenix on track for hepatitis B drug trial
30 March, 2012 by Dylan Bushell-EmblingMelbourne's Agenix (ASX:AGX) expects to be on time with an application to conduct a phase I trial of a prospective hepatitis B treatment in China.
Synchrotron funding to support ongoing research
29 March, 2012 by AusBiotechThe Australian Synchrotron has yesterday secured a $100 million, allowing the Melbourne-based facility to continue research, after the Federal and state governments pledged contributions.
Biota antiviral batters the common cold
29 March, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir.
Alchemia finalising oncology spin-off
29 March, 2012 by Dylan Bushell-EmblingBrisbane-based Alchemia (ASX:ACL) is in the last stages of planning for the proposed spin-off and IPO of its oncology unit.
Free listing on Australian biotech and medtech directories
27 March, 2012 by AusBiotechAusBiotech invites Australian companies to list their biotechnology and medical technology companies free on two national directories.
Bioniche licenses animal health products
26 March, 2012 by Dylan Bushell-EmblingCanada-based Bioniche (ASX:BNC) has scored an exclusive distribution deal covering four products for its animal health-focused Australian subsidiary.
Bionomics gets approval for ovarian cancer trial
26 March, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has been cleared by the Food and Drug Administration to commence a phase I/II clinical trial of BNC105 as a treatment for ovarian cancer.
Avexa closer to EMA approval for ATC
23 March, 2012 by Dylan Bushell-EmblingAvexa Limited (ASX:AVX) and the EMA have agreed on the path forward to gaining European approval for drug-resistant HIV treatment ATC.
